Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Roche’s Immunotherapy Drug Wins FDA Approval

XTALKS VITALS NEWS

FDA

The therapy – branded by Roche as Tecentriq – won early US Food and Drug Administration (FDA) approval this week.

Share this!

May 20, 2016 | by Sarah Massey, M.Sc.

Roche’s anti-PDL1 immunotherapy, atezolizumab, has become the first new drug in decades to be approved to treat the most common form of bladder cancer. The therapy – branded by Roche as Tecentriq – won early US Food and Drug Administration (FDA) approval this week.

Tecentriq joins Bristol-Myers Squibb's Opdivo and Merck's Keytruda as the only anti-PD1/PD-L1 drugs currently on the US market. AstraZeneca is also developing its own immunotherapy for bladder cancer.

Opdivo, Keytruda and Tecentriq are classified as checkpoint inhibitors – drugs which block expression of certain tumor proteins, allowing the cancer cells to evade the immune system. By blocking these proteins, checkpoint inhibitors can work with the body’s immune cells to allow them to identify and destroy tumor cells.

Checkpoint inhibitors like the anti-PD1/PD-L1 drugs, represent an exciting area in oncology, with clinical trials showing promising results. Former President Jimmy Carter even attributes his cancer remission to his treatment with Keytruda after chemotherapy.



Tecentriq has been approved as a second-line therapy for patients with advanced or metastatic urothelial cancer. This type of bladder cancer accounts for 90 percent of all cases of the disease.

Tecentriq reduced tumor size in 14.8 percent of patients, in a Phase II clinical trial testing the drug’s efficacy. As the immunotherapy received an accelerated approval by the FDA, the agency will require Roche to perform further clinical trials to prove its effectiveness.

The drug also led to a 26 percent response rate in the 100 patients with increased PD-L1 expression in tumor-infiltrating immune cells, and generated a complete response in 12 patients. While the most common side effects included urinary tract infections, anemia and fatigue, three participants experienced server adverse drug reactions which proved fatal.

Roche is currently testing the drug to gauge its efficacy against other cancer types, including lung and breast cancer. Additional, FDA-approved indications would not only boost sales of Tecentriq, but would also make it a key competitor for Opdivo and Keytruda. Regardless of whether Tecentriq is granted additional approvals, all three immunotherapies are expected to reach blockbuster drug status by 2020.


Keywords: Immunotherapy, FDA, Bladder Cancer


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Food Companies are Looking for the Next Sriracha

October 19, 2017 - The Sriracha trend might be coming to an end and companies are looking for the next big hot sauce star to feature in their line-up.

Featured In: Food News


CFIA Recalling Mechanically Tenderized Steaks in Canada for E. coli

October 19, 2017 - The Canadian Food Inspection Agency posted a recall for mechanically tenderized steaks at the request of Vantage Foods Inc. on Tuesday.

Featured In: Food News


Study: Gender May Be Important When Matching Blood Transfusion Recipients to Donors

October 19, 2017 - According to a new study published in JAMA, gender and a history of pregnancy among female donors may have an impact on how well blood donors and recipients can be matched.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Brexit – Separating Fact from Fiction


Evolving Best Practices for Working with Authors of Scientific Publications – Authorship and Beyond


Human Whole-Genome Sequencing in a New Era Defined by the Illumina® HiSeq X® and NovaSeq™ Platforms


Clinical Event Adjudication: Comprehensive and Efficient Dossier Review Using a Global On-Line Solution


Copyright © 2016-2017 Honeycomb Worldwide Inc.